These harrowing responses to The Cancer Letter's survey on gender bias are best represented with no interpretation or analysis.
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.This year's Cancer Progress Report from the American Association for Cancer Research provides a chilling overview of the impact COVID-19 has had on cancer.
Earlier this year, as doctors observed that patients afflicted with the novel coronavirus were dying from a cytokine release syndrome, some suggested focusing on suppressing production of interleukin-6 to control this immune response gone haywire.
FDA has granted Rhenium NanoLiposomes Fast Track Designation for the treatment of patients with recurrent glioblastoma.
Elicio Therapeutics and Moffitt Cancer Center are collaborating to characterize combination therapies pairing Elicio's CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells.
Physicians at the University of California, San Diego School of Medicine and Cofactor Genomics are working to improve the ability to predict tumor response to immunotherapy in recurrent and metastatic squamous cell carcinoma of the head and neck.
The combined use of aspirin, statins, and metformin is associated with decreased lung cancer incidence and mortality, according to a study published in the Journal of Thoracic Oncology, the journal of the International Association for the Study of Lung Cancer.
Patients treated for bladder cancer with a surgery known as radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of USC. The study appeared in the Journal of Urology.
The EA61411 study conducted by ECOG-ACRIN Cancer Research Group has begun its phase III portion.
Despite progress, adolescents and young adults face substantial cancer disparities by race/ethnicity
A new report examining cancer in adolescents and young adults defined as diagnoses occurring during ages 15 to 39, provides updated estimates of the contemporary cancer burden in this age group, predicting that 89,500 cases and 9,270 deaths will occur in 2020 in the United States. The report appears in CA: A Cancer Journal for Clinicians.
